Brief: Biohaven's Phase 2 Obesity Study With Taldefgrobep Alfa, A Novel Myostatin-Activin Pathway Inhibitor, Completes Enrollment
19/03/2026 11:57
March 19 (Reuters) - Biohaven Ltd BHVN.N: BIOHAVEN'S PHASE 2 OBESITY STUDY WITH TALDEFGROBEP ALFA, A NOVEL MYOSTATIN-ACTIVIN PATHWAY INHIBITOR, COMPLETES ENROLLMENT Source text: ID:nPn9VHmYna Further company coverage: BHVN.N ((((Reuters.Briefs@thomsonreuters.com;));))
Recent news on Biohaven
See all newsActing US FDA chief meets with rare disease groups to mend fences (updated)
Acting US FDA chief meets with rare disease groups to mend fences
Brief: Biohaven Reports New Clinical Data In Epilepsy With Opakalim, A Selective Kv7.2/7.3 Activator, Highlighting Seizure Control And Markedly Differentiated Tolerability Profile
Brief: Biohaven Files For Offering Of Up To $350 Million Common Shares - SEC Filing
Brief: Biohaven Ltd Files For Mixed Shelf Offering Size Not Disclosed - SEC Filing